JNJ vs. TAK: Johnson & Johnson vs. Takeda Pharmaceutical Stock Comparison

Company Profile

Johnson & Johnson (JNJ) and Takeda Pharmaceutical (TAK) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.

Johnson & Johnson (JNJ) trades as ordinary local shares, while Takeda Pharmaceutical (TAK) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Takeda Pharmaceutical (TAK) reports a negative beta of -0.01, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Johnson & Johnson (JNJ) has a non-negative beta of 0.21.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Johnson & Johnson (JNJ) at 20.02% sits in the top ROE quartile, while Takeda Pharmaceutical (TAK) at 0.56% is closer to the peer norm — stronger capital efficiency for JNJ.

Johnson & Johnson (JNJ) at 16.20% retains a top-quartile share of revenue as profit, ahead of Takeda Pharmaceutical (TAK) at 0.87%, which keeps about the industry-typical share.

Both Johnson & Johnson (JNJ) at 25.74% and Takeda Pharmaceutical (TAK) at 24.55% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Johnson & Johnson (JNJ) at 6.05% is around its peer norm for revenue growth, while Takeda Pharmaceutical (TAK) at -1.66% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Both Johnson & Johnson (JNJ) at 90.50% and Takeda Pharmaceutical (TAK) at 77.96% sit in the top peer quartile for EPS growth, so each is compounding per-share earnings faster than typical industry peers.

Growth Metrics

Financial Strength

Both Johnson & Johnson (JNJ) at 1.02 and Takeda Pharmaceutical (TAK) at 1.15 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Johnson & Johnson (JNJ) at 0.55 carries an industry-typical debt-to-equity mix, while Takeda Pharmaceutical (TAK) at 0.72 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Both Johnson & Johnson (JNJ) at 1.94% and Takeda Pharmaceutical (TAK) at 953.28% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

Takeda Pharmaceutical (TAK) reports payout ratio above 100% at 426.53%, meaning dividends exceeded current-period earnings and sustainability needs extra context. Meanwhile Johnson & Johnson (JNJ) reports 80.12%, ranking against industry peers normally.

Dividend Metrics

Valuation

Johnson & Johnson (JNJ) at 41.92 is near its industry’s usual P/E ratio, while Takeda Pharmaceutical (TAK) at 300.29 sits above its peer range — an unusually expensive price for TAK’s trailing earnings.

Takeda Pharmaceutical (TAK) at 0.01 sits in the cheaper P/S ratio quartile while Johnson & Johnson (JNJ) at 6.69 prices around its industry’s middle — TAK costs less per dollar of sales, though read it alongside growth and margins.

Takeda Pharmaceutical (TAK) at 1.43 looks cheap against book in the lower P/B ratio quartile, while Johnson & Johnson (JNJ) at 8.16 carries a premium in the upper quartile — a clear price-to-book gap.

Valuation Metrics